Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peresolimab in rheumatoid arthritis (Phase II, China)
CTR20223121Phase 2Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of peresolimab in rheumatoid arthritis (RA), sponsored by Eli Lilly and Company. Started Dec 2022; status: terminated.
02
Drugs
peresolimab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on CTR20223121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20223121.